Valion Bio Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Valion Bio şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-22.4%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-22.4%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Seeking Alpha • Oct 17

Tivic Health to acquire nausea treatment products from Reliefband Technologies

Health technology company Tivic Health Systems (NASDAQ:TIVC) will acquire the Reliefband product line for nausea treatment and all related assets from Reliefband Technologies. The total consideration is of up to $33.5M, of which up to $1.5M can be paid in restricted common stock. TIVC will also acquire Reliefband's Reletex-branded prescription nausea treatments. Reliefband Technologies' patented products are backed by 40 peer-reviewed clinical studies. The transaction is expected to be consummated in Q4 or Q1 2023. The nausea treatment is a $2.4B market in the U.S. and $5.5B globally, according to QY Research. The market is said to be growing at 6.5% CAGR. TIVC shares were trading +14.57% pre-market. Source: Press Release

Analiz Makalesi • Jul 15

We Think Tivic Health Systems (NASDAQ:TIVC) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: VBIO şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: VBIO şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Valion Bio Piyasaya Karşı Temettü Getirisi

VBIO temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (VBIO)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.1%
Sektör Ortalaması (Biotechs)	2.1%
Analist tahmini (VBIO) (3 yıla kadar)	n/a

Önemli Temettü: VBIO şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, VBIO şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: VBIO şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: VBIO herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Güçlü temettü ödeyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/09/09 21:25
Gün Sonu Hisse Fiyatı	2026/09/09 00:00
Kazançlar	2026/06/30
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Valion Bio, Inc. 1 Bu analistlerden 0, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Hunter Diamond	Diamond Equity Research LLC

Valion Bio Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

Valion Bio, Inc. has withdrawn its Follow-on Equity Offering.

3i LP Delivers Letter to the Board of Valion Bio

Valion Bio Entolimod Dossier Accepted for Formal Review Under Ukraine Regulatory Equivalence Pathway

Valion Bio, Inc. has filed a Follow-on Equity Offering.

New major risk - Financial position

Valion Bio, Inc. to Report Q1, 2026 Results on May 14, 2026

Valion Bio, Inc. Receives First FDA -Precedent Study Protocol from NIAID for Entolimod

Valion Bio, Inc. Appoints Melinda Lackey as General Counsel and Senior Vice President of Legal Affairs

Valion Bio, Inc., Annual General Meeting, May 28, 2026

New major risk - Share price stability

Tivic Health Systems to Present Entolimod TLR5 Agonist Lead Drug Candidate and Its Plans for an Oral Transmucosal Delivery Program for Entolimod

Tivic Health Systems, Inc. Receives Notification Of Non-Compliance With Minimum Bid Price Requirement

New major risk - Share price stability

New minor risk - Share price stability

Third quarter 2025 earnings released: US$1.97 loss per share (vs US$3.93 loss in 3Q 2024)

New major risk - Financial position

Tivic Expands Intellectual Property Portfolio

Tivic Health Systems, Inc. to Report Q3, 2025 Results on Nov 14, 2025

Tivic Health Systems, Inc. has withdrawn its Follow-on Equity Offering in the amount of $20 million.

Tivic Health Systems, Inc. Completes Verification of Entolimod Cell Line, First Step in Establishing CGMP Manufacturing for BLA Filing

Tivic Health®? Systems, Inc. Receives Two Investigational New Drug Applications for Entolimod™? for the Treatment of Acute Radiation Syndrome (ARS) and Advanced Cancers

Second quarter 2025 earnings released: US$2.19 loss per share (vs US$5.37 loss in 2Q 2024)

Tivic Health Systems, Inc. to Report Q2, 2025 Results on Aug 14, 2025

Tivic Health Systems, Inc. Announces Blake Gurfein to Step Down as Chief Scientific Officer, Effective July 4, 2025

Tivic Health Systems, Inc. Completes Optimization Study for Its Non-Invasive Vagus Nerve Stimulation Device

Tivic Health Systems, Inc., Annual General Meeting, Jun 30, 2025

First quarter 2025 earnings released: US$2.52 loss per share (vs US$17.15 loss in 1Q 2024)

Tivic Health Systems, Inc. to Report Q1, 2025 Results on May 15, 2025

Tivic Health Systems Regains Compliance with NASDAQ Minimum Bid Price Listing Rule

Full year 2024 earnings released: US$19.68 loss per share (vs US$177 loss in FY 2023)

Tivic Health Systems, Inc. to Report Fiscal Year 2024 Results on Mar 21, 2025

Tivic Health Systems, Inc. and Feinstein Institute Present New Data Showing Personalized Vagus Nerve Stimulation Method Optimizes Impact on Autonomic Nervous System

Tivic Health Systems, Inc. Appoints Michael K. Handley as Chief Operating Officer and President of Tivic Biopharma

Third quarter 2024 earnings released: US$0.23 loss per share (vs US$1.48 loss in 3Q 2023)

Enrollment Complete in Tivic Health Optimization Study for Its Non-Invasive Vagus Nerve Stimulation Device

Tivic Health Systems, Inc. to Report Q3, 2024 Results on Nov 14, 2024

Tivic Health Systems, Inc Receives Approval from Institutional Review Board for ncVNS Optimization Study, Readies for Enrollment

Tivic Health® Systems, Inc. Announces Chief Financial Officer Changes

Tivic Health Systems, Inc. has filed a Follow-on Equity Offering in the amount of $20.000001 million.

Second quarter 2024 earnings released: US$0.32 loss per share (vs US$7.16 loss in 2Q 2023)

Tivic Health Systems Receives Notification Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement

Tivic Health Systems, Inc., Annual General Meeting, Aug 09, 2024

Tivic Health Systems, Inc. Announces Board of Director Changes

First quarter 2024 earnings released: US$1.01 loss per share (vs US$10.52 loss in 1Q 2023)

Tivic Health Systems, Inc. to Report Q1, 2024 Results on May 15, 2024

Tivic Health Announces Successful Completion of Non-Invasive Vagus Nerve Stimulation Study (Vns); Demonstrates Clinically Effective Biological Changes in the Autonomic, Cardiac, and Central Nervous Systems

Tivic Health Systems, Inc. has filed a Follow-on Equity Offering.

Full year 2023 earnings released: US$10.40 loss per share (vs US$104 loss in FY 2022)

Tivic Health Announces Completion of Enrollment for Study of Novel Non-Invasive Bioelectronic Approach to Vagus Nerve Stimulation

Tivic Health Systems, Inc. Announces Termination of Ryan Sabia as Chief Operating Officer

Tivic Health Systems, Inc. Announces Launch of Second Generation of Tivic ClearUP

Third quarter 2023 earnings released: US$1.48 loss per share (vs US$26.70 loss in 3Q 2022)

Tivic Health Systems, Inc. Regains Compliance With Nasdaq Listing Requirements

Tivic Health Funded Study Begins Enrollment for Novel Non-Invasive Bioelectronic Approach to Vagus Nerve Stimulation

Second quarter 2023 earnings released: US$0.072 loss per share (vs US$0.31 loss in 2Q 2022)

Tivic Health Systems, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Tivic Health Systems, Inc. ClearUP Expands Target Market Offering to Include Individuals Who Are Sleep Deprived, Medication Restricted, and Athletes

First quarter 2023 earnings released: US$0.10 loss per share (vs US$0.23 loss in 1Q 2022)

Tivic Health Systems, Inc. to Report Q1, 2023 Results on May 15, 2023

Tivic Health Launches B2b Portal, Accelerates Healthcare Commercial Sales Expansion

Third quarter 2022 earnings released: US$0.27 loss per share (vs US$0.90 loss in 3Q 2021)

Tivic Health to acquire nausea treatment products from Reliefband Technologies

Tivic Health Systems, Inc. (NasdaqCM:TIVC) entered into an Asset Purchase Agreement to acquire Substantially all of the assets, and certain specified liabilities, of Reliefband Technologies, LLC for $33.5 million.

Second quarter 2022 earnings released: US$0.31 loss per share (vs US$0.49 loss in 2Q 2021)

We Think Tivic Health Systems (NASDAQ:TIVC) Needs To Drive Business Growth Carefully

First quarter 2022 earnings released: US$0.23 loss per share (vs US$0.55 loss in 1Q 2021)

Tivic Health Systems, Inc., Annual General Meeting, Jun 14, 2022

High number of new and inexperienced directors

Tivic Health Systems, Inc. to Report Q4, 2021 Results on Apr 19, 2022

Tivic Health Systems, Inc. Appoints Sanjay Ahuja, as Senior Vice President, Quality Assurance & Regulatory Affairs

Full year 2021 earnings released: US$2.43 loss per share (vs US$1.58 loss in FY 2020)

Tivic Health Systems, Inc. Collaborates With Leading Medical Research Hospital on First Controlled Trial to Extend Tivic’s Bioelectronic Platform

High number of new and inexperienced directors

No independent directors

Ödemelerde İstikrar ve Büyüme